What It Is
CJC-1295 with Drug Affinity Complex (DAC) is a synthetic, long-acting analogue of growth hormone-releasing hormone (GHRH). It is a modified version of the first 29 amino acids of GHRH, designed to have a much longer half-life and a more sustained effect on growth hormone (GH) release. The key innovation in CJC-1295 with DAC is the addition of the Drug Affinity Complex, which allows the peptide to bind to albumin, a protein in the blood. This binding protects the peptide from rapid degradation and clearance, significantly extending its duration of action.
How It Works
The primary mechanism of action for CJC-1295 with DAC is to stimulate the anterior pituitary gland to release more growth hormone. Unlike synthetic growth hormone, which provides an external source of the hormone, CJC-1295 with DAC works by amplifying the body's own natural GH-releasing pathways. The GHRH portion of the molecule binds to GHRH receptors on the pituitary gland, triggering the synthesis and release of GH. The DAC component, by binding to albumin, creates a circulating reservoir of the peptide, providing a slow and steady stimulation of the pituitary over an extended period. This results in a sustained elevation of both GH and, consequently, insulin-like growth factor 1 (IGF-1) levels.
Key Research
Several studies have investigated the pharmacokinetics, pharmacodynamics, and safety of CJC-1295 with DAC. A key study by Teichman et al. (2006) in healthy adults demonstrated that a single subcutaneous injection of CJC-1295 with DAC resulted in a dose-dependent increase in mean plasma GH concentrations by 2- to 10-fold for six days or more, and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 days. The half-life of the peptide was estimated to be between 5.8 and 8.1 days. The study concluded that CJC-1295 with DAC was safe and well-tolerated at the tested doses.
Another study by Ionescu et al. (2006) found that CJC-1295 with DAC increased trough and mean GH secretion and IGF-I production while preserving the natural pulsatile release of GH. This is a significant finding, as it suggests that the peptide may be able to augment GH levels without disrupting the body's natural hormonal rhythms.
However, the development of CJC-1295 with DAC has not been without setbacks. A Phase II clinical trial investigating the peptide for the treatment of HIV-associated lipodystrophy was halted in 2006 after the death of a participant. While the exact cause of death and its relationship to the study drug were investigated, the event led to the discontinuation of the trial and cast a shadow over the peptide's safety profile Aidsmap (2006).
Further research has continued to explore the potential of CJC-1295 and other GHRH analogues. A study by Alba et al. (2006) in mice demonstrated that once-daily administration of CJC-1295 was able to maintain normal body composition and growth in GHRH knockout mice, further supporting its potential as a therapeutic agent for growth hormone deficiency.
Benefits
Research suggests that the increased levels of GH and IGF-1 resulting from CJC-1295 with DAC administration may offer a range of potential benefits. These include:
- Increased muscle mass and strength: Growth hormone is a key regulator of muscle growth and development.
- Reduced body fat: GH and IGF-1 can promote lipolysis, the breakdown of fats.
- Improved sleep quality: Growth hormone is primarily released during deep sleep, and there is a complex interplay between GH and sleep cycles.
- Enhanced recovery from injuries: IGF-1 plays a crucial role in tissue repair and regeneration.
- Increased bone density: Growth hormone is important for maintaining bone health.
Risks & Side Effects
Despite the potential benefits, there are also risks and side effects associated with CJC-1295 with DAC. The most serious concern is the potential for adverse cardiovascular events, as highlighted by the patient death in the lipodystrophy trial. Other reported side effects include injection site reactions (redness, pain, and swelling), headaches, and water retention. The long-acting nature of the DAC version also means that any side effects may be prolonged. It is crucial to note that CJC-1295 with DAC is not approved by the FDA for any medical use and is available for research purposes only.
Practical Considerations
In the context of research, CJC-1295 with DAC has been studied at various dosages. The study by Teichman et al. used single doses of 30, 60, 125, and 250 µg/kg, and multiple doses of 30 or 60 µg/kg. Administration is typically via subcutaneous injection. Due to its long half-life, dosing is infrequent, often once or twice a week in research settings.
The Bottom Line
CJC-1295 with DAC is a potent, long-acting GHRH analogue that has demonstrated the ability to significantly increase GH and IGF-1 levels in a sustained manner. While research suggests potential benefits for muscle growth, fat loss, and other physiological processes, the safety profile of the peptide remains a concern, particularly given the discontinuation of a major clinical trial. As with any research peptide, the long-term effects of CJC-1295 with DAC are not fully understood.
This information is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide or hormone therapy protocol.
